IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

- In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline - - 56% of participants reached AOSBP below 130 mmHg at Week 48 - - Long-term treatment with lorundrostat was well tolerated, with no new clinically relevant safety findings beyond Launch-HTN - - U.S. FDA review of lorundrostat is underway, with a PDUFA target

Context & Analysis

Cardiovascular risk management remains one of the most commercially important areas in healthcare, not only because hypertension is widespread, but because it sits at the intersection of pharmacy sales, insurance costs, hospital utilization, and workplace productivity. For Philippine businesses, chronic disease is an expense issue. Employers absorb sick leave and medical allowances, insurers price policies based on claims experience, and pharmacies compete on patient adherence programs. A therapy that offers a new mechanism of action can therefore matter beyond the clinic: it may reshape prescribing patterns, treatment guidelines, and the economics of long-term care.

Lorundrostat’s significance lies in its approach to aldosterone, a hormone linked to blood pressure regulation and fluid balance. If regulators ultimately view the drug as a useful option for patients who do not respond adequately to existing treatments, it could become a premium specialty product rather than a mass-market commodity. That distinction is important in the Philippines, where access to new pharmaceuticals often depends on import channels, distribution partnerships, price sensitivity, and whether private or public payers see value. Even before local availability, Philippine pharmaceutical distributors, medical technology firms, and healthcare investors may watch U.S. regulatory signals as a leading indicator for future commercialization.

The next milestone is the U.S. Food and Drug Administration decision, which will clarify the label and, by extension, the patient population the drug is meant to serve. A broad approval would support stronger commercial demand, while a narrower label would limit reach and increase physician education needs. Investors should also watch for pricing, payer coverage, and competitive responses from other cardiometabolic drug makers. For Filipino consumers, the practical question is longer-term: if a new hypertension treatment reaches the market, can it be accessed at an affordable price without delaying standard care? In a system where out-of-pocket spending still shapes treatment choices, commercial success may depend less on the science alone and more on how payers, pharmacies, and regulators work together.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

Asante Reports Q3 2026 Operating & Financial Results and Issues Clarification Regarding November 12, 2026 Press Release

6h ago

Island Passage Exploration Provides Exploration Update and Announces a Webinar with John Robins and Quinton Hennigh on November 18, 2026

6h ago

Crown Point Announces Operating and Financial Results for the Three and Nine Months Ended September 30, 2026

6h ago

GrabrFi Tops $1 Billion in Payments, Raises $6 Million to Launch Dollar Accounts for Businesses Abroad

6h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected